These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28402204)

  • 1. Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
    Tijssen RYG; Kraak RP; Lu H; Mifek JG; Carlyle WC; Donohoe DJ; De Winter RJ; Koch KT; Wykrzykowska JJ
    Expert Rev Med Devices; 2017 May; 14(5):325-334. PubMed ID: 28402204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technical overview on the MiStent coronary stent.
    McCLAIN JB; Carlyle WC; Donohoe DJ; Ormiston JA
    Minerva Cardioangiol; 2016 Oct; 64(5):560-71. PubMed ID: 27152624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging.
    Kobayashi N; Ito Y; Yamawaki M; Araki M; Sakai T; Sakamoto Y; Mori S; Tsutsumi M; Nauchi M; Honda Y; Tokuda T; Makino K; Shirai S; Hirano K
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):515-522. PubMed ID: 29159531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
    Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population.
    Zhao YJ; Teng M; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Loh JP; Chan MY
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29316284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
    Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
    Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
    Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
    JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
    de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
    Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial.
    Kaiser C; Galatius S; Jeger R; Gilgen N; Skov Jensen J; Naber C; Alber H; Wanitschek M; Eberli F; Kurz DJ; Pedrazzini G; Moccetti T; Rickli H; Weilenmann D; Vuillomenet A; Steiner M; Von Felten S; Vogt DR; Wadt Hansen K; Rickenbacher P; Conen D; Müller C; Buser P; Hoffmann A; Pfisterer M;
    Circulation; 2015 Jan; 131(1):74-81. PubMed ID: 25411159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives.
    Iglesias JF; Roffi M; Degrauwe S; Secco GG; Aminian A; Windecker S; Pilgrim T
    Expert Rev Med Devices; 2017 Oct; 14(10):773-788. PubMed ID: 28889769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial.
    Yuan F; Chen X; Song X; Wang D; Zhang Z; Li W; Li Z; Li H; Chen X; Huo Y; Wang L; Lu C; Lu Q; Xu B; Li W; Lyu S;
    Chin Med J (Engl); 2014; 127(14):2561-6. PubMed ID: 25043067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
    Smits PC; Hofma S; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; Vuillomenet A; Serra A; Nouche RT; den Heijer P; van der Ent M
    Lancet; 2013 Feb; 381(9867):651-60. PubMed ID: 23374650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents.
    Jakobsen L; Christiansen EH; Maeng M; Hansen KN; Kristensen SD; Bøtker HE; Terkelsen CJ; Jensen SE; Raungaard B; Madsen M; Lassen JF; Jensen LO
    EuroIntervention; 2017 Dec; 13(11):1336-1344. PubMed ID: 28846543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.
    Lupi A; Gabrio Secco G; Rognoni A; Lazzero M; Fattori R; Sheiban I; Sante Bongo A; Bolognese L; Agostoni P; Porto I
    Catheter Cardiovasc Interv; 2014 May; 83(6):E193-206. PubMed ID: 24478247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
    Buszman PP; Michalak MJ; Pruski M; Fernandez C; Jelonek M; Janas A; Savard C; Gwiazdowska-Nowotka B; Żurakowski A; Wojakowski W; Buszman PE; Milewski K
    Cardiol J; 2016; 23(6):657-666. PubMed ID: 27976797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.